e-learning
resources
Vienna 2009
Sunday, 13.09.2009
Various backgrounds in diffuse parenchymal lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Cryptogenic organising pneumonia – clarithromycin treatment – factors influencing treatment results and relapses
E. Radzikowska, E. Wiatr, R. Langfort, I. Bestry, M. Plodziszewska, K. Roszkowski (Warsaw, Poland)
Source:
Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease
Session:
Various backgrounds in diffuse parenchymal lung disease
Session type:
Thematic Poster Session
Number:
743
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Radzikowska, E. Wiatr, R. Langfort, I. Bestry, M. Plodziszewska, K. Roszkowski (Warsaw, Poland). Cryptogenic organising pneumonia – clarithromycin treatment – factors influencing treatment results and relapses. Eur Respir J 2009; 34: Suppl. 53, 743
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Eosinophilic pneumonia – Our own experience with diagnosis and treatment
Source: Annual Congress 2012 - The good clinical practice: useful case report
Year: 2012
Comorbidities – risk factors for relapsed pulmonary TB
Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities
Year: 2009
Treatment of sarcoidosis – pentoxifylline
Source: Annual Congress 2009 - Pleural and parenchymal diseases
Year: 2009
Pro-vasopressin (copeptin) in patients with community-acquired pneumonia – influence of antibiotic pre-treatment; results from the German competence network CAPNETZ
Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia
Year: 2009
Clinical evaluation in 14 cases of diffuse alveolar hemorrhage – Relationship between initial findings and prognosis –
Source: Annual Congress 2010 - Rare diffuse lung diseases
Year: 2010
Surgical treatment of pulmonary sequestration – 15-years experience
Source: Annual Congress 2010 - Congenital lesions and rare pathology
Year: 2010
Erdosteine – A new drug in the treatment of chronic rhinosinusitis
Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use
Year: 2012
Drug interaction in tuberculosis treatment – The role of pharmacists
Source: Annual Congress 2012 - Tuberculosis: clinical findings II
Year: 2012
Chronic necrotizing aspergillosis – review of 10 cases
Source: Annual Congress 2009 - Complications of respiratory infections: impact of comorbidities and infections caused by Aspergillus
Year: 2009
Pulmonary TB -diabetes melitus – an unfavorable association
Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities
Year: 2009
Risk factors for severe bronchiolitis – A retrospective study
Source: Annual Congress 2012 - Paediatric respiratory epidemiology. Wheeze: where, how and why?
Year: 2012
Causing pathogenes in the severest AECOPD – one year analysis
Source: Annual Congress 2009 - Exacerbations of COPD and bronchiectasis: aetiology and treatment
Year: 2009
Heliox administration in patients with COPD exacerbation – Technical aspects
Source: Annual Congress 2010 - Mechanical ventilation and weaning
Year: 2010
Oral glucocorticoid treatment of severe asthma – Current practice in the US
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010
Cryptogenic organising pneumonia – just a manifestation of community acquired pneumonia? A retrospective analysis from 1995 to 2004
Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease
Year: 2009
Pulmonary tuberculosis – Still a challenging diagnosis
Source: Annual Congress 2011 - Clinical tuberculosis
Year: 2011
Patients‘ knowledge about inhalation therapy in pulmology – One year after intervention
Source: Annual Congress 2011 - Medical education
Year: 2011
Chronic meningitis – a rare form of onset of tuberculosis infection in infants
Source: Annual Congress 2009 - Tuberculosis at different age groups
Year: 2009
Destroyed lung secondary to tuberculosis – Surgical options
Source: Annual Congress 2012 - Surgery for infections and congenital diseases
Year: 2012
Haemoptysis in children – some respiratory causes
Source: Annual Congress 2009 - Diagnosis and treatment of viral respiratory infections in early childhood
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept